CellaVision ABCHIX:CEVIS 96 Return-on-Tangible-Asset is 15.49% as of Mar. 2026, which is 46% below its 10-year median of 28.52. GuruFocus rates CHIX:CEVIS with a GF Score™ of 96/100 and a GF Value™ of kr231.79. The stock has 1 warning sign investors should review. Among 855 Medical Devices & Instruments companies, CellaVision AB ranks better than 97.19% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. CellaVision AB's annualizedNet Income for the quarter that ended in Mar. 2026 was kr90.0 Mil. CellaVision AB's average total tangible assets for the quarter that ended in Mar. 2026 was kr581.3 Mil. Therefore, CellaVision AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 15.49%.
The historical rank and industry rank for CellaVision AB's Return-on-Tangible-Asset or its related term are showing as below:
CHIX:CEVIs'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 23.91 Med: 28.52 Max: 32.14
Current: 23.91
During the past 13 years, CellaVision AB's highest Return-on-Tangible-Asset was 32.14%. The lowest was 23.91%. And the median was 28.52%.
CHIX:CEVIs's Return-on-Tangible-Asset is ranked better than 97.19% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.62
vs CHIX:CEVIs: 23.91
CellaVision AB (CHIX:CEVIs) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
CellaVision AB Return-on-Tangible-Asset Related Terms
CellaVision AB Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for CellaVision AB's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CEVIS vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, CellaVision AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where CellaVision AB's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 15.49% mean?
CellaVision AB (CHIX:CEVIS) has a Return-on-Tangible-Asset of 15.49% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on CellaVision AB and its competitors. This is 46% below median its historical median of 28.52. Over the past decade, CellaVision AB's Return-on-Tangible-Asset has ranged from 23.91 to 32.14. According to the industry distribution chart, CellaVision AB ranks #24 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 2.8%.
Is CellaVision AB's Return-on-Tangible-Asset too high?
CellaVision AB's current Return-on-Tangible-Asset of 15.49% is 46% below median its 10-year median of 28.52. Over the past 10 years, this metric has ranged from a low of 23.91 to a high of 32.14. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.62. CellaVision AB's value of 15.49% is 2398.4% above this industry median. Based on the distribution chart, CellaVision AB ranks #24 out of 855 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, CellaVision AB has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #24 out of 855 companies for Return-on-Tangible-Asset. This places CellaVision AB in the top 3% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.62. CellaVision AB's value of 15.49% is 2398.4% above this benchmark. Historically, CellaVision AB's own Return-on-Tangible-Asset has ranged from 23.91 to 32.14 over the past decade. While the company's 10-year median is 28.52 vs. the industry median of 0.62, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.62, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current Return-on-Tangible-Asset of 15.49% is 2398.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current Return-on-Tangible-Asset is 15.49%, which is 46% below median its own 10-year median of 28.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
CellaVision AB (CHIX:CEVIS) has a current Return-on-Tangible-Asset of 15.49%. The stock's GF Value™ is kr231.79, compared to a current price of kr160.20 — trading 30.9% below its estimated fair value. The current Return-on-Tangible-Asset is 15.49%, which is 46% below median its 10-year median of 28.52 and 2398.4% above the Medical Devices & Instruments industry median of 0.62. CellaVision AB's overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For CellaVision AB (CHIX:CEVIS), the current Return-on-Tangible-Asset is 15.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CHIX:CEVIS) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of kr160.20 is trading 30.9% below its estimated GF Value™ of kr231.79.
Key valuation signals for CHIX:CEVIS:
Return-on-Tangible-Asset: 15.49% (46% below median its 10-year median of 28.52)
GF Value™: kr231.79 vs. price of kr160.20 (30.9% below fair value)
Industry Position: 2398.4% above the Medical Devices & Instruments median (#24 of 855)
No single metric tells the full story. See the CHIX:CEVIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
96GF Score
Get the complete analysis for CHIX:CEVIS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CEVIS has been successfully added to your 
